GLUE

Monte Rosa Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)Nasdaq<br>Emerging growth company

Total Trades

22

Buys

1

Sells

15

Largest Trade

N/A

Insiders

8

Institutional Funds

117

Inst. Value

$1M+

Activist Filings

39

Insider Trades

InsiderTitleTypeValueSharesPriceDate
Dunn EdmundPrincipal Accounti…SELL$1K–$15K139$17.96Mar 5, 2026
Warmuth MarkusPresident & CEOSELL$50K–$100K5K$17.92Mar 4, 2026
Dunn EdmundPrincipal Accounti…SELL$100K–$500K26K$18.09Mar 2, 2026
Dunn EdmundPrincipal Accounti…EXERCISE$100K–$500K26K$13.41Mar 2, 2026
Janku FilipChief Medical Offi…SELL$100K–$500K9K$19.50Feb 24, 2026
Warmuth MarkusPresident & CEOSELL$100K–$500K5K$23.49Jan 9, 2026
Nickson PhilipChief Business & L…GRANTN/A28KJan 5, 2026
Nickson PhilipChief Business & L…SELL$15K–$50K3K$15.17Jan 5, 2026
Champoux JenniferCOOGRANTN/A35KJan 5, 2026
Champoux JenniferCOOSELL$15K–$50K3K$15.17Jan 5, 2026
Dunn EdmundPrincipal Accounti…SELL$15K–$50K1K$15.17Jan 5, 2026
Warmuth MarkusPresident & CEOGRANTN/A90KJan 5, 2026
Warmuth MarkusPresident & CEOSELL$100K–$500K10K$15.17Jan 5, 2026
Janku FilipChief Medical Offi…SELL$15K–$50K3K$15.17Jan 5, 2026
Janku FilipChief Medical Offi…GRANTN/A31KJan 5, 2026
Townson SharonChief Scientific O…SELL$15K–$50K3K$15.17Jan 5, 2026
Townson SharonChief Scientific O…GRANTN/A35KJan 5, 2026
Dunn EdmundPrincipal Accounti…SELL$1K–$15K2K$4.45Jun 4, 2025
Leo Chandra P.DirectorBUY$50K–$100K10K$5.84Mar 25, 2025
Versant Venture Capital VI, L.P.10% OwnerSELL$1M+158K$9.44Oct 30, 2024
Versant Venture Capital VI, L.P.10% OwnerSELL$1M+1.1M$6.53Sep 24, 2024
Dunn EdmundPrincipal Accounti…SELL$1K–$15K1K$4.04Jun 5, 2024
🔓Seeing ranges? Sign in for exact trade values — free forever

Activist & 5%+ Owners

SC 13D/13G filings — investors holding 5%+ of outstanding shares

BIOTECHNOLOGY VALUE FUND L P

SC 13G/A · Feb 17, 2026

3.1%

2.1M shares

Adam Goulburn

SC 13G/A · Jan 21, 2026

8.7%

5.7M shares

Versant Venture Capital VI, L.P.

SC 13D/A · Jan 9, 2026

3.4%

2.2M shares

T. Rowe Price Associates, Inc.

SC 13G/A · Nov 14, 2025

7.5%

4.6M shares

Avoro Capital Advisors LLC

SC 13G/A · Nov 14, 2025

0.0%

0 shares

Versant Venture Capital VI, L.P.

SC 13D/A · Nov 12, 2025

5.1%

3.3M shares

The Vanguard Group

SC 13G/A · Oct 31, 2025

4.8%

3.0M shares

TCG Crossover GP II, LLC

SC 13G · Oct 17, 2025

3.6%

2.2M shares

Adam Goulburn

SC 13G · Oct 3, 2025

7.7%

4.8M shares

Avoro Capital Advisors LLC

SC 13G/A · Aug 14, 2025

6.1%

3.7M shares

FMR LLC

SC 13G/A · Jun 6, 2025

2.8%

1.8M shares

BIOTECHNOLOGY VALUE FUND L P

SC 13G/A · May 15, 2025

4.7%

2.9M shares

SUVRETTA CAPITAL MANAGEMENT, LLC

SC 13G · Apr 16, 2025

5.5%

3.4M shares

Avoro Capital Advisors LLC

SC 13G/A · Feb 14, 2025

7.1%

4.3M shares

BlackRock, Inc.

SC 13G · Feb 4, 2025

6.3%

3.8M shares

BIOTECHNOLOGY VALUE FUND L P

SC 13G · Jan 31, 2025

3.7%

2.3M shares

The Vanguard Group

SC 13G · Jan 31, 2025

5.1%

3.2M shares

10.8%

6.6M shares

FMR LLC

SC 13G/A · Nov 12, 2024

8.3%

5.1M shares

Versant Venture Capital VI, L.P. 2.

SC 13D/A · Oct 30, 2024

6.6%

4.1M shares

Versant Venture Capital VI, L.P. 2.

SC 13D/A · Sep 24, 2024

8.3%

5.1M shares

New Enterprise Associates 17, L.P.

SC 13D/A · Aug 12, 2024

12.5%

7.7M shares

Versant Venture Capital VI, L.P. 2.

SC 13D/A · Aug 12, 2024

11.1%

6.8M shares

New Enterprise Associates 17, L.P.

SC 13D/A · May 14, 2024

15.2%

7.7M shares

10.2%

5.1M shares

Baker Bros. Advisors LP

SC 13G · Feb 14, 2024

9.8%

4.9M shares

0.0%

0 shares

BlackRock, Inc.

SC 13G/A · Feb 14, 2024

4.7%

2.4M shares

9.9%

4.9M shares

Avoro Capital Advisors LLC

SC 13G/A · Feb 14, 2024

9.1%

4.5M shares

Versant Venture Capital VI, L.P.

SC 13D/A · Nov 9, 2023

13.7%

6.8M shares

1.3%

631K shares

7.6%

3.7M shares

Avoro Capital Advisors LLC

SC 13G/A · Feb 14, 2023

8.9%

4.3M shares

BlackRock, Inc.

SC 13G · Feb 3, 2023

7.4%

3.6M shares

1.6%

731K shares

Avoro Capital Advisors LLC

SC 13G · Feb 11, 2022

7.1%

3.3M shares

10.4%

4.9M shares

8.9%

4.1M shares

View on Google Finance →